Q3 FY26 · Ended Sep 30, 2026 · View SEC filing
U.S. dialysis earns more than the whole company
The ancillary businesses grew fastest but lost money this quarter, so every dollar of group profit came from U.S. dialysis.
For investorsWhat has to hold for the U.S. dialysis margin
For foundersRunning fixed capacity on recurring demand
The gain came below operating income: partners took a smaller share and last year's other losses did not recur.
Earnings per share grew faster than profit because the share count fell, a policy funded by cash and borrowing.
Patients need dialysis several times a week, so demand is scheduled and the centers run as steadily filled fixed capacity.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes DaVita from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
